Senolytic-loaded asymmetric wound dressing for targeted senescent cell clearance in diabetic wound healing.
Summary
An asymmetric fabric-based platform delivering the senolytic ABT-263 selectively reduced senescent cells and accelerated wound closure in diabetic mice, with preserved biocompatibility and no detectable systemic toxicity. Single-cell RNA-seq of human diabetic ulcers informed target selection and mechanistic validation.
Key Findings
- Single-cell RNA-seq mapped senescence-associated changes in human diabetic foot ulcer tissues.
- Navitoclax (ABT-263) was the most effective senolytic in fibroblasts and endothelial cells.
- ABT-263-loaded asymmetric dressing reduced senescent cell burden and enhanced wound healing in diabetic mice.
- No detectable systemic toxicity and maintained biocompatibility were observed with localized delivery.
Clinical Implications
If validated in humans, localized senolytic dressings could offer a new adjunctive therapy for diabetic foot ulcers, reducing systemic exposure while enhancing healing.
Why It Matters
Introduces a localized senolytic strategy with strong preclinical efficacy and a favorable safety profile, addressing a major barrier in translating senolytics for chronic wounds.
Limitations
- Preclinical mouse model; human efficacy and safety remain untested.
- Long-term local safety and optimal dosing regimens were not fully characterized.
Future Directions
Conduct dose-ranging and durability studies, evaluate wound microbiome interactions, and initiate early-phase clinical trials for diabetic foot ulcers.
Study Information
- Study Type
- Preclinical experimental study
- Research Domain
- Treatment
- Evidence Level
- V - Preclinical in vitro and in vivo evidence without human clinical data
- Study Design
- OTHER